A5084872095- Statistical Methods in Clinical Trials
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Causal Inference Techniques
- Biomedical Ethics and Regulation
- Statistical Methods and Inference
- Cancer Genomics and Diagnostics
- Biosimilars and Bioanalytical Methods
- Advancements in Battery Materials
- Genomics and Rare Diseases
- Advanced Battery Technologies Research
- Advanced Battery Materials and Technologies
- Computational Drug Discovery Methods
- Optimal Experimental Design Methods
- Pharmaceutical Economics and Policy
- Colorectal Cancer Treatments and Studies
- Supercapacitor Materials and Fabrication
- Economic and Financial Impacts of Cancer
- SARS-CoV-2 and COVID-19 Research
- Nuclear Materials and Properties
- Lysosomal Storage Disorders Research
- Influenza Virus Research Studies
- COVID-19 Impact on Reproduction
- Synthesis of Tetrazole Derivatives
- Nanoparticle-Based Drug Delivery
- Autonomous Vehicle Technology and Safety
Beijing Institute of Technology
2023-2025
Chongqing University of Technology
2023-2025
Astellas Pharma (Japan)
2025
North China University of Technology
2025
Shanghai East Hospital
2024
Second Affiliated Hospital of Zhejiang University
2024
Zunyi Medical University
2023
Zimmer Biomet (United States)
2021-2023
Boston University
2022-2023
Center for Global Development
2023
Abstract LiFePO 4 is extensively used as a cathode material in lithium‐ion batteries because of its high safety profile, affordability, and extended cycle life. Nevertheless, inherently low transport kinetics restricted electronic conductivity considerably limit rate performance. Furthermore, the failure mechanisms specific to various cycling rates are not well examined. This study presents functional interface layer designed regulate rate‐dependent behavior . At elevated charge/discharge...
Abstract Whole exome sequencing (WES) is used to identify mutations in a patient’s tumor DNA that are predictive of behavior, including the likelihood response or resistance cancer therapy. WES has mutation limit detection (LoD) at variant allele frequencies (VAF) 5%. Putative called ≤ 5% VAF frequently due errors, therefore reporting these subclonal incurs risk significant false positives. Here we performed ~ 1000 × on fresh-frozen and formalin-fixed paraffin-embedded (FFPE) tissue biopsy...
COVID-19 outbreak has rapidly evolved into a global pandemic. The impact of on patient journeys in oncology represents new risk to interpretation trial results and its broad applicability for future clinical practice. We identify key intercurrent events that may occur due trials with focus time-to-event endpoints discuss considerations pertaining the other estimand attributes introduced ICH E9 addendum. propose strategies handle related events, depending their relationship malignancy...
The use of biomarkers to guide adaptive enrichment designs in oncology trials presents a promising strategy for increasing trial efficiency and improving the chance identifying efficacious treatment right population. With well-defined biomarker, such can enhance study power reduce costs by adapting focus populations. However, existing may not have sufficiently flexible interim decision-making rules, testing procedures, sample size re-estimation, limiting their full potential. In this...
This study collected site and spatial morphological data from 63 typical aging community activity spaces extracted 12 types through statistical analysis. A parametric modeling tool was used to generate models. Based on clearly defined design variables constraints, the NSGA-II multi-objective optimization algorithm applied minimize summer thermal discomfort, maximize winter comfort, annual average sunlight duration, resulting in 342 Pareto optimal solutions. The first explored linear...
An addendum of the ICH E9 guideline on Statistical Principles for Clinical Trials was released in November 2019 introducing estimand framework. This new framework aims to align trial objectives and statistical analyses by requiring a precise definition inferential quantity interest, that is, estimand. explicitly accounts intercurrent events, such as switching anticancer therapies analysis overall survival (OS), gold standard oncology. Traditionally, OS confirmatory studies is analyzed using...
The estimand framework requires a precise definition of the clinical question interest (the estimand) as different ways accounting for "intercurrent" events post randomization may result in scientific questions. initiation subsequent therapy is common oncology trials and considered an intercurrent event if start such occurs prior to recurrence or progression event. Three possible account this analysis are censor at initiation, consider (including death) that occur before after therapy,...
Combining different treatment regimens provides an effective approach to induce a synergistic effect and overcome resistance monotherapy. The challenge is that, given the large number of existing monotherapies, possible combinations huge new potentially more efficacious compounds may become available any time during drug development. To address this challenge, we propose flexible Bayesian combination platform design with adaptive shrinkage (ComPAS), which allows for dropping futile...
Pseudomonas aeruginosa ( P. ) can be an important causative factor for severe infections in humans, especially patients with respiratory infections.
The coronavirus pandemic has brought public attention to the steps required produce valid scientific clinical research in drug development. Traditional ethical principles that guide remain guiding compass for physicians, patients, health officials, investigators, developers and public. Accelerating process of delivering safe effective treatments vaccines against COVID-19 is a moral imperative. apparent clash between regulated system phased randomized trials urgent need requires leveraging...
Biomarkers that predict efficacy and safety for a given drug therapy become increasingly important treatment strategy evaluation in personalized medicine. Methodology appropriately identifying validating such biomarkers is critically needed, although it very challenging to develop, especially trials of terminal diseases with survival endpoints. The marker‐by‐treatment predictiveness curve serves this need by visualizing the effect on as function biomarker each treatment. In article, we...